Human genetics implicates a BACH2-NRF2 axis in fetal hemoglobin activation

Inside every red blood cell, a tiny molecular machine called hemoglobin carries oxygen from the lungs to the rest of the body. For most of us, this machine is built in a specific way that works perfectly for adult life. But before we are born, our bodies use a slightly different version of this machine, known as fetal hemoglobin, which is exceptionally good at grabbing oxygen from a mother's blood. Shortly after birth, our genes usually switch off the fetal version and turn on the adult version. For people with certain blood disorders, such as sickle cell disease or beta-thalassemia, this switch is a problem. Their adult hemoglobin is defective, causing pain and organ damage. However, if they could keep producing the fetal version, it would act as a natural remedy, smoothing out the rough edges of their disease and allowing them to live healthier lives. Scientists have long known that some people naturally produce more of this fetal hemoglobin than others, and they have spent years hunting for the genetic switches that control this process.

A team of researchers recently took a massive step forward in this search by looking at the genetic code of nearly 28,000 people from diverse backgrounds, including populations in Europe, Africa, and Asia. They were not just looking for the switches they already knew about; they wanted to find new ones. By comparing the DNA of people with high levels of fetal hemoglobin against those with low levels, they identified a new genetic region that had never been linked to this process before. This region contains a gene called BACH2. The researchers found that a specific variation in the DNA of this gene acts like a dimmer switch. In people who naturally have higher levels of fetal hemoglobin, this variation turns down the activity of the BACH2 gene. When the researchers tested this in the lab, they confirmed that reducing the amount of BACH2 protein in blood cells caused those cells to start making fetal hemoglobin again.

The story gets more interesting when the researchers looked at how BACH2 actually works. They discovered that BACH2 acts as a brake on the production of fetal hemoglobin by blocking another protein called NRF2. Under normal conditions, BACH2 sits on the DNA near the genes that make fetal hemoglobin and keeps them silent. It does this by physically competing with NRF2 for the same spot on the genetic code. NRF2 is a protein that, when it gets a chance to bind to the DNA, turns on the fetal hemoglobin genes. The researchers showed that when BACH2 is removed or its activity is reduced, NRF2 is free to bind to the DNA and switch the fetal hemoglobin genes back on. This interaction happens directly at the site where the genes are located, and the two proteins seem to physically interact with each other, with BACH2 effectively holding NRF2 back.

Crucially, the team found that this new pathway operates completely independently of the most famous regulator of fetal hemoglobin, a protein called BCL11A. For years, medical research has focused heavily on turning off BCL11A to treat blood disorders, and while that approach works, it is not the only way. The new study shows that the BACH2 and NRF2 system is a separate, parallel track. The researchers demonstrated that even if BCL11A is still present and active, reducing BACH2 is enough to allow NRF2 to activate the fetal hemoglobin genes. This means that doctors might eventually be able to use two different strategies at the same time—targeting both BCL11A and the BACH2-NRF2 axis—to get even better results for patients.

To prove exactly how this works, the scientists used precise tools to edit the DNA of blood cells in a dish. They targeted the specific spots on the DNA where BACH2 and NRF2 try to bind. When they altered the DNA to make it harder for BACH2 to hold on, the cells produced more fetal hemoglobin. Conversely, when they changed the DNA to make it harder for NRF2 to bind, the fetal hemoglobin production dropped. This confirmed that the balance between these two proteins is the key. The researchers also observed that when BACH2 is reduced, NRF2 gathers in specific clusters inside the cell nucleus, right next to the active fetal hemoglobin genes, acting like a localized engine for production. This process does not seem to rely on the usual stress signals that typically activate NRF2, suggesting it is a unique mechanism specific to blood cell development.

The findings offer a fresh perspective on how we might treat difficult blood diseases. While the genetic variation the team found does not increase fetal hemoglobin as dramatically as some other known mutations, the fact that it was discovered through a large, diverse study gives scientists high confidence that it is a real and important biological lever. The study does not claim to have a cure ready for immediate use, but it has identified a new, valid target for future therapies. By showing that BACH2 restrains NRF2 to keep fetal hemoglobin off, the researchers have opened a new door. They have provided a clear map of a molecular interaction that can be manipulated, suggesting that drugs or gene therapies designed to weaken BACH2 or boost NRF2 could one day help patients with sickle cell disease and beta-thalassemia by reactivating their body's own natural defense system.